Fibrin matrix of thrombus (None in standard use; sometimes referred to as "fibrin clot" or "thrombus matrix" informally, but no widely accepted abbreviation.)

The fibrin matrix of a thrombus is a three-dimensional network of polymerized fibrin protein, generated from fibrinogen through thrombin-catalyzed clotting. This matrix provides mechanical integrity and stability to the thrombus, serving as a scaffold that embeds platelets, red blood cells, leukocytes, and, at times, neutrophil extracellular traps. The structure and density of the fibrin matrix influence the susceptibility of a clot to fibrinolysis and are associated with the pathogenesis and outcome of various thrombotic diseases, including myocardial infarction, stroke, and pulmonary embolism. Fibrin forms not only a fibrous scaffold inside clots but can also organize into protective films or layers on the clot surface, influencing clot stability and protection from infection. While it is not a discrete molecular target, drugs that degrade or prevent formation of the fibrin matrix are central in thrombolytic and antithrombotic therapy[1][2][3].

Other names

Fibrin clotFibrin scaffoldThrombus fibrin networkFibrin meshwork

Fibrinolytics: Catalyze the conversion of plasminogen to plasmin, which enzymatically degrades fibrin matrix, leading to thrombus dissolution[2][3]. Anticoagulants: Prevent the generation of thrombin, thereby reducing fibrin formation, but do not directly act on existing fibrin matrix.